ARGX · Nasdaq · CIK 0001697862
ARGENX SE
ARGENX SE’s most recent SEC filing in our snapshot is a Form 6-K filed on Oct 22, 2026. Its EDGAR record lists 0 Form 4 insider filings from the 12 months before our last refresh.
SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.
Company overview
- Legal name (as filed)
- ARGENX SE
- Ticker
- ARGX
- SEC Central Index Key (CIK)
- 0001697862
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (code 2836)
- Business address
- ZWIJNAARDE
- State or country of incorporation
- Netherlands
- Fiscal year ends
- December 31
- SEC filer category
- Large accelerated filer
- Position in SEC ticker list
- #295 of the 3,000 companies we track
Five-year financial highlights
Full-year figures from ARGENX SE’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.
| Item | FY2021 ended Dec 31, 2021 | FY2022 ended Dec 31, 2022 | FY2023 ended Dec 31, 2023 | FY2024 ended Dec 31, 2024 | FY2025 ended Dec 31, 2025 |
|---|---|---|---|---|---|
| Revenue | $497.3M | $10.0M | $35.5M | — | — |
| Net income | -$408.3M | -$709.6M | -$295.1M | $833.0M | $1.3B |
| Diluted EPS | -$7.99 | -$13.05 | -$5.16 | $12.78 | $19.57 |
| Total assets | $2.9B | $3.1B | $4.5B | $6.2B | $8.7B |
| Cash and equivalents | $1.3B | $800.7M | $2.0B | $1.5B | $3.5B |
XBRL tags used: revenue = RevenueFromContractsWithCustomers; netIncome = ProfitLoss; assets = Assets; eps = DilutedEarningsLossPerShare; cash = CashAndCashEquivalents. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.
How to read these numbers
Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.
Advertisement
Latest key reports
The most recent filing of each major report type, even if it falls outside the 40 newest filings below.
Recent SEC filings
The 40 newest documents filed by or about ARGENX SE, by form type:
| Filed | Form | What it is | Original |
|---|---|---|---|
| Oct 22, 2026 | 6-K | Report of a foreign private issuer· period Sep 30, 2026 | Document · Index |
| Oct 19, 2026 | 6-K | Report of a foreign private issuer· period Oct 19, 2026 | Document · Index |
| Oct 8, 2026 | 6-K | Report of a foreign private issuer· period Oct 8, 2026 | Document · Index |
| Sep 29, 2026 | 6-K | Report of a foreign private issuer· period Sep 29, 2026 | Document · Index |
| Aug 27, 2026 | 6-K | Report of a foreign private issuer· period Aug 27, 2026 | Document · Index |
| Aug 27, 2026 | SC TO-T/A | SC TO-T/A | Document · Index |
| Aug 19, 2026 | SC TO-T/A | SC TO-T/A | Document · Index |
| Aug 17, 2026 | 6-K | Report of a foreign private issuer· period Aug 17, 2026 | Document · Index |
| Aug 14, 2026 | SCHEDULE 13G/A | Passive beneficial ownership report (over 5%) | Document · Index |
| Aug 6, 2026 | SC TO-T/A | SC TO-T/A | Document · Index |
| Aug 6, 2026 | SC TO-T | SC TO-T | Document · Index |
| Aug 3, 2026 | 6-K | Report of a foreign private issuer· period Aug 3, 2026 | Document · Index |
| Jul 28, 2026 | SC TO-C | SC TO-C | Document · Index |
| Jul 27, 2026 | SC TO-C | SC TO-C | Document · Index |
| Jul 27, 2026 | 6-K | Report of a foreign private issuer· period Jul 27, 2026 | Document · Index |
| Jul 23, 2026 | 6-K | Report of a foreign private issuer· period Jun 30, 2026 | Document · Index |
| Jun 23, 2026 | 6-K | Report of a foreign private issuer· period Jun 23, 2026 | Document · Index |
| Jun 3, 2026 | 6-K | Report of a foreign private issuer· period Jun 3, 2026 | Document · Index |
| May 11, 2026 | 6-K | Report of a foreign private issuer· period May 8, 2026 | Document · Index |
| May 7, 2026 | 6-K | Report of a foreign private issuer· period Mar 31, 2026 | Document · Index |
| May 6, 2026 | 6-K | Report of a foreign private issuer· period May 6, 2026 | Document · Index |
| May 6, 2026 | SCHEDULE 13G/A | Passive beneficial ownership report (over 5%) | Document · Index |
| Apr 20, 2026 | 6-K | Report of a foreign private issuer· period Apr 20, 2026 | Document · Index |
| Mar 20, 2026 | 6-K | Report of a foreign private issuer· period Mar 20, 2026 | Document · Index |
| Mar 19, 2026 | 20-F | Annual report of a foreign private issuer· period Dec 31, 2025 | Document · Index |
| Mar 19, 2026 | 6-K | Report of a foreign private issuer· period Dec 31, 2025 | Document · Index |
| Mar 6, 2026 | 6-K | Report of a foreign private issuer· period Mar 6, 2026 | Document · Index |
| Feb 26, 2026 | 6-K | Report of a foreign private issuer· period Dec 31, 2025 | Document · Index |
| Feb 26, 2026 | 6-K | Report of a foreign private issuer· period Feb 26, 2026 | Document · Index |
| Jan 13, 2026 | 6-K | Report of a foreign private issuer· period Jan 13, 2026 | Document · Index |
| Jan 12, 2026 | 6-K | Report of a foreign private issuer· period Jan 12, 2026 | Document · Index |
| Jan 5, 2026 | 6-K | Report of a foreign private issuer· period Jan 5, 2026 | Document · Index |
| Dec 18, 2025 | UPLOAD | UPLOAD | Document · Index |
| Dec 17, 2025 | S-8 | Registration of employee benefit plan securities | Document · Index |
| Dec 15, 2025 | 6-K | Report of a foreign private issuer· period Dec 15, 2025 | Document · Index |
| Nov 18, 2025 | 6-K | Report of a foreign private issuer· period Nov 18, 2025 | Document · Index |
| Nov 14, 2025 | SCHEDULE 13G/A | Passive beneficial ownership report (over 5%) | Document · Index |
| Oct 30, 2025 | 6-K | Report of a foreign private issuer· period Sep 30, 2025 | Document · Index |
| Oct 29, 2025 | 6-K | Report of a foreign private issuer· period Oct 29, 2025 | Document · Index |
| Oct 15, 2025 | 6-K | Report of a foreign private issuer· period Oct 15, 2025 | Document · Index |
Insider filing activity
0 Form 4 filings appear in ARGENX SE’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.
Advertisement
Other companies in Biological Products, (No Diagnostic Substances)
- AMGN AMGEN INC
- GILD GILEAD SCIENCES, INC.
- MRNA Moderna, Inc.
- RVMD Revolution Medicines, Inc.
- BIIB BIOGEN INC.
- BNTX BioNTech SE
- EXEL EXELIXIS, INC.
- NBIX NEUROCRINE BIOSCIENCES INC
All 61 companies in Biological Products, (No Diagnostic Substances)
On Amazon
Popular tools for investors
As an Amazon Associate I earn from qualifying purchases.
Source
- U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001697862 and XBRL company facts. ARGENX SE on EDGAR.
- Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.
Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.
Advertisement